Pharmaceutical dissolution is the process by which a medicinal product typically a tablet, capsule, or powder dissolves in a liquid medium that simulates physiological fluids, releasing its active pharmaceutical ingredient (API). This process is fundamental to understanding how a drug performs in the human body, as it directly influences bioavailability, absorption rate, and therapeutic effectiveness.
Dissolution testing is a cornerstone of pharmaceutical development and quality control across Europe. It ensures that drug products meet the stringent safety, efficacy, and consistency standards mandated by the European Medicines Agency (EMA) and national regulatory authorities. The test is indispensable for formulation optimization, batch release testing, bioequivalence studies, and marketing authorization applications, making it central to regulatory compliance throughout the drug lifecycle.
According to BIS Research, Europe pharmaceutical dissolution market was valued at $208.6 million in 2024 and is projected to reach $409.5 million by 2033, growing at a CAGR of 7.78% during the forecast period (2024–2033).
• Stringent EMA and National Regulatory Requirements
• Rising Generic Drug Production
• Increasing Pharmaceutical R&D Investments
• Growing Complexity of Drug Formulations
• Expansion of Biopharmaceuticals and Biosimilars
• High Capital Costs of Automated Systems
• Lack of Standardized Methods for Novel Drug Delivery Systems
• Shortage of Skilled Professionals
• Complexity of Biorelevant Method Development
• Regulatory Interpretation Variability Across Countries
• Maintenance and Calibration Burden
• ?Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest-of-Europe
Explore the Full TOC and Download Report Sample >>
The European pharmaceutical dissolution market reflects the region’s commitment to high-quality, safe, and effective medicines. While challenges related to cost, skills, and standardization persist, increasing automation and regulatory alignment position the market for sustained long-term growth.
-BIS Research Analyst Team
It measures how a drug releases its active ingredient in liquid media.
It ensures drug quality, bioavailability, and EMA regulatory compliance.
It is expected to grow at a CAGR of 7.78% from 2024 to 2033.
BIS Research offers KOL-based insights, rigorous segmentation, and strategic advisory across software, hardware, and sensing tech domains.
